Latest Conference Coverage

The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.

The assistant professor in the Department of Neurology at the University of Wisconsin spoke about the differences between health disparities and health equity in epilepsy care at the 2022 AES Conference. [WATCH TIME: 3 minutes]

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center spoke about his experience in a debate on surgery in genetic disorders at the 2022 AES Conference. [WATCH TIME: 3 minutes]

The Baldwin Keyes professor of neurology at Thomas Jefferson University, spoke with us at the 2022 AES Conference about the definition of a seizure. [WATCH TIME: 3 minutes]

The executive vice president of Global Head of Research and Development at Jazz Pharmaceuticals, spoke on the results from the BECOME study presented at the 2022 AES Conference. [WATCH TIME: 6 minutes]

The professor of neurology at the University of Toronto talked about 3 conditions that were discussed during the epilepsy therapies symposium at the 2022 AES Conference. [WATCH TIME: 5 minutes]

The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease, and the new ways to approach prevention. [WATCH TIME: 4 minutes]

The professor of neurology at the University of Toronto spoke at the 2022 AES Conference about genetic approaches to comorbidities for patients with epilepsy. [WATCH TIME: 5 minutes]

The director of research at the TSC Alliance spoke with us at the 2022 AES Conference about future research to be conducted on patients with TSC such as the PREVeNT trial. [WATCH TIME: 6 minutes]

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided perspective on the reasons to not solely rely on anti-amyloid treatments to treat Alzheimer disease. [WATCH TIME: 3 minutes]

The executive director of Banner Alzheimer’s Institute discussed the efforts being done within the field to improve prevention and therapeutics for Alzheimer disease.

At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about sleep testing for patients with epilepsy. [WATCH TIME: 3 minutes]

The associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital spoke about sleep disorders and epilepsy in adults at the 2022 AES annual meeting. [WATCH TIME: 5 minutes]

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided background on a study presented at CTAD 2022 assessing the efficacy of prominent, up-and-coming anti-amyloid therapies. [WATCH TIME: 7 minutes]

The professor of clinical geriatric epidemiology at Karolinska Institutet provided perspective on the FINGERS trial, the first study to show it is possible to prevent cognitive decline using a multidomain lifestyle intervention.

The chief medical officer of Alzheon detailed the phase 2 safety findings of ALZ-801, and the lack of amyloid-related imaging abnormalities observed. [WATCH TIME: 3 minutes]

The pediatric neurologist and epileptologist at the University of Michigan's Mott Children's Hospital spoke at the 2022 AES conference about disparities that currently exist in epilepsy care. [WATCH TIME: 4 minutes]

James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.

The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]

Chaired by Robert Bermel, MD, of Cleveland Clinic, the presentations also feature Jeffrey Cohen, MD; Amy Kunchock, MBBS, MMed; and Brandon Moss, MD. [WATCH TIME: 1 hour, 30 minutes]

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen Children's Medical Center of Northwell Health, spoke about the association between sleep disorders and pediatric epilepsy at the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

The chief medical officer of Alzheon discussed the impact a therapy like ALZ-801 can have on the overall Alzheimer community considering its effects on carriers of APOE e4 alleles. [WATCH TIME: 3 minutes]

Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.

The pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]

Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.